ClinicalTrials.Veeva

Menu

Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®

Aesculap logo

Aesculap

Status

Terminated

Conditions

Total Hip Arthroplasty Revision

Treatments

Device: Structan®

Study type

Observational

Funder types

Industry

Identifiers

NCT02019433
AAG-O-H-1212

Details and patient eligibility

About

Implant Survival as well as clinical and radiological Follow-Up of acetabular Titan-Augment Structan®

Enrollment

5 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Minimum age 18 years
  • Indication for cementless hip arthroplasty with acetabular defects that need Allograft or titanium augment
  • Patient consent for study participation
  • Physical and mental willingness to participate in the follow-ups

Exclusion criteria

  • Patient not available for follow-up
  • Increased anesthetics risks for the patient according to the "American Society of Anesthesiology": ASA IV
  • Tumor
  • Alcohol- or Drug abuse
  • Permanent cortisone therapy
  • Clinically relevant infection
  • (Planned) pregnancy

Trial design

5 participants in 1 patient group

Structan®
Treatment:
Device: Structan®

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems